University Of Oklahoma

The University of Oklahoma Health Sciences Center (Board of Regents of the University of Oklahoma Health Sciences Center), a public academic health research institution based in Oklahoma City, operates as a prime recipient and contractor for federal biomedical research, clinical services, and graduate medical education delivered to the National Institutes of Health, Department of Veterans Affairs, Department of Defense, and other federal agencies. The center competes across the full federal landscape with no set-aside posture, holding a leading position in NIH-funded cancer biology and preclinical drug development research alongside substantial service delivery contracts for radiopharmaceuticals, medical education, and clinical support.

OUHSC's competitive footprint spans 1,716 prime awards (86% of total) and 286 sub-awards across 110 distinct federal customers, with 2,002 total awards generating $484.3 million in combined potential value, though obligated dollars ($2.21 billion) reflect the mature, renewal-heavy nature of its academic research portfolio. The top-five customer agencies by award count account for 44% of recent volume: the Department of the Army (293 awards), National Cancer Institute (162 awards, $324.6 million), Veterans Integrated Service Network 19 (148 awards, $53.5 million), broader NIH (142 awards), and Navy Bureau of Medicine and Surgery (138 awards, $4.3 million). NCI dollars dominate potential value (67% of the top-five customers' combined value), reflecting OUHSC's strength in cancer prevention and treatment research. VISN 19 radiopharmaceutical and medical equipment orders anchor the VA relationship; DoD growth reflects recent defense health-relevant oncology and translational work. SCI-reportable service contracts (those above $150,000) show invoiced revenue of $24.2 million across FY2022–FY2025, with 73 prime records and workforce averaging 16–28 FTEs per fiscal year; median government-paid rates sit at $116.49/hour, spanning $46–$394/hour across the percentile range.

Capability portfolio centers on preclinical and translational cancer drug development, cardiovascular and metabolic disease research, biomedical sciences graduate training, clinical health services, and specialty medical products. Representative prime work includes a $149.995 million NCI IDIQ for the PREVENT Cancer Preclinical Drug Development Program (Jan 2024–Jan 2029) housing multiple delivery orders: a $1.234 million order (Sept 2025) for mitochondria-targeted honokiol development for lung cancer prevention, and a $1.148 million order (Sept 2026) for triple-negative breast cancer vaccine preclinical efficacy. A $2.077 million NHLBI award (Sept 2025) investigates estrogen signaling in chronic asthma; a $2.13 million DHA award (May 2026) establishes the Oklahoma Center for Biomedical Research Excellence in Sensory Biology. Across SCI-reportable contracts, median hourly rates ($116/hr) reflect a mix of research scientists, clinicians, and support personnel; sub-engagement averages 22% of contractor hours, with 46 named subcontractors across prime contracts, indicating OUHSC typically builds delivery teams in-house for research but engages specialized partners for imaging, biostatistics, and genomic analysis.

OUHSC operates the Stephenson Cancer Center (an NCI-designated cancer center) and holds a single-award Basic Ordering Agreement with Navy Bureau of Medicine and Surgery (May 2025–Apr 2035) that serves as a framework for tuition reimbursement, radiopharmaceutical supplies, sequencing services, expert witness testimony, and medical equipment procurement from the Department of Veterans Affairs, National Cancer Institute, and other agencies. Recent task orders under this BOA include $77.8 thousand for tuition reimbursement (July 2025), $358.2 thousand for radiopharmaceuticals (Oct 2025), and $59.3 thousand for DNA sequencing (Feb 2025). OUHSC also places work under the NCI's PREVENT Cancer IDIQ and holds leadership positions in national cooperative trial networks (SWOG, Alliance, NRG Oncology) reflected in sub-awards to NCI consortium partners and participation in multi-site clinical trial development.

Activity has remained steady at 90–159 awards per year from 2023–2025, with a slight decline to 92 awards in 2026 and early 2027 showing only 2 awards (reflecting source data lag). A recompete cliff looms: 122 awards (combined potential value $28.6 million) face ultimate completion in the next 24 months, creating near-term re-competition risk for radiopharmaceutical and medical education contracts with VISN 19 and Navy, alongside preclinical drug development task orders under the NCI IDIQ. As a state-controlled research university, OUHSC does not sub-award to external primes in the traditional corporate sense; rather, it partners with peer institutions (Oklahoma Medical Research Foundation, Oklahoma State University, University of Oklahoma Norman Campus) as research collaborators on complex, multi-site NIH and DoD studies. Federal grant recipients within OUHSC include faculty principals performing basic biomedical research (neuroscience, metabolic disease, cancer biology) under NIH R01/R21 mechanisms and cooperative agreement programs (DHA Military Medical Research & Development, NSF CIVIC Infrastructure, CDC injury prevention). Grant work emphasizes cancer prevention (smoking cessation mHealth interventions, prostate cancer screening), cardiovascular aging, neurodegeneration, and health disparities in American Indian and underserved populations—aligned with OUHSC's mission as an academic health center in a state ranked among the lowest in public health outcomes.